SunRegen Selected for Phase I of BaseLaunch Accelerator

---

August 10, 2017

SunRegen SBC003 project was accepted as a phase I project by BaseLaunch, which is a healthcare accelerator backed by Novartis, Pfizer, Johnson & Johnson, and Roche.

The SunRegen BaseLaunch Phase I project gives the SBC003 team mentorship, funding, and access to a global healthcare network. Additionally, the program connects SunRegen with top pharmaceutical companies, including Novartis, Pfizer, Johnson & Johnson, and Roche. These connections expose startups to industry leaders and potential investors, helping them accelerate their innovative projects.

SunRegen participates actively in the BaseLaunch Phase I program, where the team receives guidance on regulatory strategy, clinical development, and commercialization of therapies. Furthermore, BaseLaunch provides workshops, hands-on training, and mentorship that allow startups to refine project strategies and optimize research processes. This experience strengthens SunRegen’s capabilities and accelerates its mission to develop treatments for neurodegenerative disorders.

The program also encourages collaboration among selected startups. SunRegen shares knowledge, learns best practices, and forms partnerships with other biotech innovators. In addition, this network fosters collaboration, increases credibility, and helps attract future funding opportunities and research partnerships.

Through its participation, SunRegen demonstrates its commitment to translating scientific research into practical therapies. The BaseLaunch Phase I program enables the company to expand its reach, gain visibility in the global healthcare ecosystem, and make measurable progress in advancing treatments for neurodegenerative disorders.

For more details, visit BaseLaunch and explore SunRegen research initiatives to learn about ongoing projects. The program’s partner companies—Novartis, Pfizer, Johnson & Johnson, and Roche—also provide support and industry expertise to participating startups.